| 产品编号 | bs-43773P |
| 英文名称 | Recombinant human SLC39A6 protein, C-His (HEK293) |
| 中文名称 | 重组人雌激素调节蛋白LIV1 |
| 别 名 | S39A6_HUMAN; S39A6_HUMAN; Estrogen-regulated protein LIV-1; Solute carrier family 39 member 6; Zrt- and Irt-like protein 6; ZIP-6; LIV1; ZIP6; |
| 克 隆 号 | |
| 理论分子量 | 35.5 kDa |
| 检测分子量 | |
| 性 状 | Liquid |
| 纯 度 | ≥ 85% as determined by SDS-PAGE. |
| 缓 冲 液 | PBS (pH=7.4) |
| 保存条件 | Stored at -70℃ or -20℃. Avoid repeated freeze/thaw cycles |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 产品介绍 |
LIV-1 is expressed as two isoforms. LIV-1 is a multi-pass cell membrane protein that is 749 amino acids in length and is expressed abundantly in breast, prostate, placenta, kidney, pituitary and corpus callosum, as well as in cells derived from various types of cancers affecting the glands, cervix and lungs. LIV-1 is a member of the ZIP transporter protein family which consists of 14 members that transport zinc. LIV-1 transports zinc from its position on the plasma membrane into the cytosol of the cell and contains a histidine-rich transmembrane domain which is thought to bind zinc and aid in its transportation. LIV-1 is thought to be important for zinc uptake in neuroblastoma cells and may also be crucial for maintaining zinc homeostasis, a process which aids in the prevention of cancer and disease. Activated estrogen receptors are thought to regulate LIV-1 expression at the level of transcription, via the mRNA precursor to LIV-1 which associates with estrogen receptors that are activated by growth factors and estradiol. LIV-1 is upregulated in hormone-rich tissue, including breast and cervical cancer, where it is thought to affect cell motility and may play an important role in tumor development and metastasis. Conversely, less aggressive tumors may contain high levels of LIV-1 that could lead to apoptosis, indicating a dual role for LIV-1 in tumor suppression. SWISS: Q13433 Gene ID: 25800 |
| 产品图片 |
The purity of the protein is greater than 85% as determined by reducing SDS-PAGE.
|
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
